Interrogating open issues in cancer precision medicine with patient-derived xenografts
2017 · Nature reviews. Cancer · 656 citations
https://doi.org/10.1038/nrc.2016.140
K
Kristel Kemper
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
111
Papers
7.3K
Citations
28
h-index
31
i10-index
Kristel Kemper is an academic researcher from Genmab (Netherlands). The author has contributed to research in topics: Cancer Cells and Metastasis & Cancer Immunotherapy and Biomarkers & Cancer Genomics and Diagnostics. The author has an h-index of 28, co-authored 95 publications.
ORCID: 0000-0003-3229-6902Papers by this author
worksIntra‐ and inter‐tumor heterogeneity in a vemurafenib‐resistant melanoma patient and derived xenografts
2015 · EMBO Molecular Medicine · 139 citations
https://doi.org/10.15252/emmm.201404914
BRAFV600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts
2016 · Cell Reports · 83 citations
https://doi.org/10.1016/j.celrep.2016.05.064
Targeting <scp>CDK</scp> 2 overcomes melanoma resistance against <scp>BRAF</scp> and Hsp90 inhibitors
2018 · Molecular Systems Biology · 66 citations
https://doi.org/10.15252/msb.20177858
Parallel In Vivo and In Vitro Melanoma RNAi Dropout Screens Reveal Synthetic Lethality between Hypoxia and DNA Damage Response Inhibition
2014 · Cell Reports · 42 citations
https://doi.org/10.1016/j.celrep.2014.10.024
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
2024 · Nature Communications · 24 citations
https://doi.org/10.1038/s41467-023-44308-6
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat